{
    "clinical_study": {
        "@rank": "36961", 
        "arm_group": {
            "arm_group_label": "NNC0113-0987", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of the trial is to evaluate the optimal dosing\n      conditions for GLP-1 analogue NNC0113-0987 when administered orally in healthy male\n      subjects."
        }, 
        "brief_title": "Evaluation of Optimal Dosing Conditions for GLP-1 Analogue NNC0113-0987 When Administered Orally in Healthy Male Subjects", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Healthy"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male aged 18 between 55 years (both inclusive) at the time of signing informed\n             consent\n\n          -  Good general health based on medical history, physical examination, and results of\n             vital signs, electrocardiogram and laboratory safety tests performed during the\n             screening visit, as judged by the investigator\n\n          -  Body mass index (BMI) between 18.5 and 29.9 kg/m^2 (both inclusive)\n\n        Exclusion Criteria:\n\n          -  History of, or presence of, cancer, diabetes or any clinically significant\n             cardiovascular,respiratory, metabolic, renal, hepatic, gastrointestinal,\n             endocrinological, haematological, dermatological, venereal, neurological, psychiatric\n             diseases or other major disorders, as judged by the investigator\n\n          -  Blood pressure above 140 mmHg systolic and/or above 90 mmHg diastolic or pulse above\n             90 beats per minute at the screening visit\n\n          -  Smoking more than 5 cigarettes or the equivalent per day (including use of nicotine\n             substitute products)\n\n          -  History of significant drug abuse, or a positive drug test at the screening visit\n\n          -  Any blood draw in excess of 25 mL in the past month, or donation of blood or plasma\n             in excess of 400 mL within the 3 months preceding the screening visit"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02094521", 
            "org_study_id": "NN9926-4047", 
            "secondary_id": [
                "2012-003855-13", 
                "U1111-1133-7097"
            ]
        }, 
        "intervention": {
            "arm_group_label": "NNC0113-0987", 
            "description": "For oral administration. All subjects will be treated for 10 consecutive days with five days on 5 mg NNC0113-0987 followed by five days on 10 mg NNC0113-0987. Dose escalation is chosen to increase gastrointestinal tolerability.", 
            "intervention_name": "NNC0113-0987", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 11, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Harrow", 
                    "country": "United Kingdom", 
                    "zip": "HA1 3UJ"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "Evaluation of Optimal Dosing Conditions for GLP-1 Analogue NNC0113-0987 When Administered Orally in Healthy Male Subjects", 
        "overall_contact": {
            "email": "clinicaltrials@novonordisk.com", 
            "last_name": "Novo Nordisk"
        }, 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Area under the NNC0113-0987 plasma concentration time curve", 
            "safety_issue": "No", 
            "time_frame": "From time 0 to 24 hours after the 10th dosing"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02094521"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Maximum observed NNC0113-0987 plasma concentration", 
            "safety_issue": "No", 
            "time_frame": "0 to 24 hours after the 10th dosing"
        }, 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}